Eancell Enhances CDMO Capabilities with AI Integration in Manufacturing Science and Technology
Eancell, a contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, announced on the 9th its initiative to enhance its capabilities by integrating artificial intelligence (AI) technology into its Manufacturing Science and Technology (MSAT) processes.
In March, Eancell began collaborating with SpiderCore, a company founded by AI experts from KAIST, to develop AI-driven cell and gene therapy solutions and establish a smart production platform. The company is working to create an integrated smart production system that connects AI with its manufacturing and quality technologies for cell and gene therapies, facilitating drug candidate design and optimization, predicting clinical success rates, and advancing production processes.
MSAT is a critical function that involves transferring the candidate substances and process technologies held by clients to a real GMP (Good Manufacturing Practice) production environment and optimizing them for large-scale production. Eancell has focused on intricately designing commercializable processes that go beyond simple contract manufacturing and systematizing key process variables and quality standards. With the introduction of AI, the company aims to further enhance its expertise in the fields of cell and gene therapies, maximizing the effects of reducing development timelines and costs for its clients.
Leveraging its capabilities in cell and gene therapy development and production, Eancell has established an integrated system that connects process development, technology transfer, manufacturing, and quality management. The company is conducting process designs optimized for the characteristics of client candidate substances and production purposes, mainly with specialized personnel holding masters and doctoral degrees. In the future, Eancell plans to integrate AI-based data analysis to further enhance batch success rates and process reproducibility.
Eancell is committed to advancing the field of cell and gene therapies through innovative technology and strategic collaborations, positioning itself as a leader in the CDMO sector.
In March, Eancell began collaborating with SpiderCore, a company founded by AI experts from KAIST, to develop AI-driven cell and gene therapy solutions and establish a smart production platform. The company is working to create an integrated smart production system that connects AI with its manufacturing and quality technologies for cell and gene therapies, facilitating drug candidate design and optimization, predicting clinical success rates, and advancing production processes.
MSAT is a critical function that involves transferring the candidate substances and process technologies held by clients to a real GMP (Good Manufacturing Practice) production environment and optimizing them for large-scale production. Eancell has focused on intricately designing commercializable processes that go beyond simple contract manufacturing and systematizing key process variables and quality standards. With the introduction of AI, the company aims to further enhance its expertise in the fields of cell and gene therapies, maximizing the effects of reducing development timelines and costs for its clients.
Leveraging its capabilities in cell and gene therapy development and production, Eancell has established an integrated system that connects process development, technology transfer, manufacturing, and quality management. The company is conducting process designs optimized for the characteristics of client candidate substances and production purposes, mainly with specialized personnel holding masters and doctoral degrees. In the future, Eancell plans to integrate AI-based data analysis to further enhance batch success rates and process reproducibility.
Eancell is committed to advancing the field of cell and gene therapies through innovative technology and strategic collaborations, positioning itself as a leader in the CDMO sector.
Like
0
Upvote0
- PrevNew Public Spaces to be Developed in Hyundai Motors Global Business Complex in Gangnam, Seoul
- NextSamsung Emphasizes Human-Centered Design in Galaxy S26 and Galaxy Buds4 Series
이동*
정말 최고예요!
한혜*
정말 미래적인 기술이네요. 어서 빨리 상용화 되었으면 좋겠습니다.
홍한*
이런 소식 정말 좋아요.
No comments yet.